Jun 2025
Wegovy, a once-weekly injectable weight-loss medication, is now available in Australia. Designed for individuals with a BMI of 30 or more, Wegovy supports weight loss when combined with a reduced-calorie diet and increased physical activity. Learn how it works, its effectiveness, and potential side effects.
Read MoreJun 2025
Wegovy may offer unexpected benefits beyond weight loss. A clinical trial revealed that individuals taking Wegovy during the COVID-19 pandemic had a 33% lower risk of dying from the virus compared to those on a placebo.
Read MoreMay 2025
The diabetes medication semaglutide has been shown to significantly reduce the risk of kidney failure and death in individuals with type 2 diabetes and chronic kidney disease. The clinical trial, conducted by University or New South Wales’ researchers and published in the New England Journal of Medicine, found that the medication can reduce the risk of kidney failure, slow the significant loss of kidney function, and lower the risk of death from kidney or cardiovascular causes.
Read MoreApr 2025
As of the end of March, the KP.2 variant accounted for about 4% of infections in the U.S., according to the CDC, while its parent strain, JN.1, was responsible for over 50% of infections at that time. By early May, KP.2 had surged to make up about 28% of infections, surpassing JN.1 as the dominant variant. KP.2 is one of several variants referred to as “FLiRT variants,” named after the specific mutations they possess. The emergence of these variants is particularly significant as experts determine the composition of the fall COVID vaccine.
Read MoreJan 2025
Leading scientists warn that influenza is the pathogen most likely to spark a new pandemic soon. An international survey presented at the ESCMID Global Congress (formerly ECCMID) in Spain, indicated that 57% of senior disease experts believe a strain of the flu virus will be the cause of the next global outbreak of a deadly infectious illness. The belief that influenza poses the greatest pandemic threat is supported by extensive research demonstrating its constant evolution and mutation, according to Jon Salmanton-García from Cologne University, who led the study.
Read MoreDec 2024
Our sense of taste helps regulate the pace of our eating, and understanding this mechanism may lead to new approaches for weight loss. Professor Zachary Knight, a scientist researching hunger and weight control, has highlighted how our brains signal that we’ve had enough to eat. When people start feeling full, their eating pace slows down. For decades, scientists believed this change in eating speed was driven solely by signals from the stomach and intestines to the brain. However, a new study from Professor Knight’s lab at UC San Francisco reveals another process at work that begins as soon as food is tasted.
Read MoreNov 2024
British journalist and author, Johann Hari, recently published an opinion piece in the New York Times titled “A Year on Ozempic Taught Me We’re Thinking About Obesity All Wrong”. Johann went from 92kgs to 73kgs within a year of starting his Ozempic journey, all the while grappling with a persistent feeling of guilt and immorality, as if his use of Ozempic was somehow cheating the process.
Read MoreOct 2024
On the opposite side of the spectrum from malnutrition, obesity stands out as one of the most glaring and yet often overlooked public health challenges of our time. Strangely juxtaposed with undernutrition, the worldwide prevalence of overweight and obesity, often referred to as “globesity,” is on the rise world over.
Read MoreOct 2024
GLP-1 agonists like semaglutide are making strides in improving type-2 diabetes management and weight-related health. Recent research has shown that they can lower the risk of heart attacks and strokes and also help quiet the food noise. However, as demand for semaglutide rises, so do assertions that using it is cheating in weight loss or taking the easy way out.
Read MoreSep 2024
Wegovy, initially approved for weight loss and sharing the same active ingredient (semaglutide) as the diabetes medication Ozempic, has received approval for treating heart disease by the US Food and Drug Administration (FDA). This decision comes after the release of new clinical evidence showcasing the effectiveness of semaglutide in reducing cardiovascular events among non-diabetic individuals.
Read More
Load More